Tadalafil has biologic activity in human melanoma. Results of a pilot trial with Tadalafil in patients with metastatic Melanoma (TaMe)

OncoImmunology

Volumn 6, Issue 9, 2017, Pages

  Hassel, Jessica C ^a   Jiang, Huanhuan ^b,c   Bender, Carolin ^a   Winkler, Julia ^a   Sevko, Alexandra ^b   Shevchenko, Ivan ^b   Halama, Niels ^a   Dimitrakopoulou Strauss, Antonia ^a   Haefeli, Walter E ^a   Jäger, Dirk ^a   Enk, Alexander ^a   Utikal, Jochen ^b   Umansky, Viktor ^b  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

Immunotherapy; melanoma; myeloid suppressor cells; phosphodiesterase 5 inhibitor; tadalafil

Indexed keywords

TADALAFIL;

ADULT; AGED; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CLINICAL OUTCOME; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TISSUE LEVEL; DRUG TOLERABILITY; FATIGUE; FEMALE; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; HEADACHE; HUMAN; IMMUNOHISTOCHEMISTRY; LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY; MALE; METASTATIC MELANOMA; MIDDLE AGED; NAUSEA AND VOMITING; OPEN STUDY; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PILOT STUDY; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; SHORT FORM 12; T LYMPHOCYTE ACTIVATION; TUMOR ASSOCIATED LEUKOCYTE; WEIGHT REDUCTION;

EID: 85028547765     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2017.1326440     Document Type: Article

References (49)

1. Erdmann F, Lortet-Tieulent J, Schuz J, Zeeb H, Greinert R, Breitbart EW, Bray F. International trends in the incidence of malignant melanoma 1953-2008–are recent generations at higher or lower risk? Int J Cancer 2013; 132(2):385-400; PMID:22532371; https://doi.org/10.1002/ijc.27616
2. Pflugfelder A, Kochs C, Blum A, Capellaro M, Czeschik C, Dettenborn T, Dill D, Dippel E, Eigentler T, Feyer P, et al. Malignant melanoma S3-guideline “diagnosis, therapy and follow-up of melanoma.” J Dtsch Dermatol Ges 2013; 11 Suppl 6:1-116, 1-126; PMID:24028775; https://doi.org/10.1111/ddg.12113_suppl
3. Eggermont AM, Spatz A, Robert C. Cutaneous melanoma. Lancet 2014; 383(9919):816-27; PMID:24054424; https://doi.org/10.1016/S0140-6736(13)60802-8
4. Gajewski TF, Woo SR, Zha Y, Spaapen R, Zheng Y, Corrales L, Spranger S. Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment. Curr Opin Immunol 2013; 25(2):268-76; PMID:23579075; https://doi.org/10.1016/j.coi.2013.02.009
5. Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in cancer therapy. J Clin Oncol 2015; 33(17):1974-82; PMID:25605845; https://doi.org/10.1200/JCO.2014.59.4358
6. Nishikawa H, Sakaguchi S. Regulatory T cells in cancer immunotherapy. Curr Opin Immunol 2014; 27:1-7; PMID:24413387; https://doi.org/10.1016/j.coi.2013.12.005
7. Biswas SK, Allavena P, Mantovani A. Tumor-associated macrophages:functional diversity, clinical significance, and open questions. Semin Immunopathol 2013; 35(5):585-600; PMID:23657835; https://doi.org/10.1007/s00281-013-0367-7
8. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 2012; 12(4):253-68; PMID:22437938; https://doi.org/10.1038/nri3175
9. Parker KH, Beury DW, Ostrand-Rosenberg S. Myeloid-derived suppressor cells:critical cells driving immune suppression in the tumor microenvironment. Adv Cancer Res 2015; 128:95-139; PMID:26216631; https://doi.org/10.1016/bs.acr.2015.04.002
10. Kumar V, Patel S, Tcyganov E, Gabrilovich DI. The nature of myeloid-derived suppressor cells in the tumor microenvironment. Trends Immunol 2016; 37(3):208-20; PMID:26858199; https://doi.org/10.1016/j.it.2016.01.004
11. Solito S, Marigo I, Pinton L, Damuzzo V, Mandruzzato S, Bronte V. Myeloid-derived suppressor cell heterogeneity in human cancers. Ann NY Acad Sci 2014; 1319:47-65; PMID:24965257; https://doi.org/10.1111/nyas.12469
12. Filipazzi P, Huber V, Rivoltini L. Phenotype, function and clinical implications of myeloid-derived suppressor cells in cancer patients. Cancer Immunol Immunother 2012; 61(2):255-63; PMID:22120756; https://doi.org/10.1007/s00262-011-1161-9
13. Poschke I, Kiessling R. On the armament and appearances of human myeloid-derived suppressor cells. Clin Immunol 2012; 144(3):250-68; PMID:22858650; https://doi.org/10.1016/j.clim.2012.06.003
14. Bronte V, Brandau S, Chen SH, Colombo MP, Frey AB, Greten TF, Mandruzzato S, Murray PJ, Ochoa A, Ostrand-Rosenberg S, et al. Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nat Commun 2016; 7:12150; PMID:27381735; https://doi.org/10.1038/ncomms12150
15. Jiang H, Gebhardt C, Umansky L, Beckhove P, Schulze TJ, Utikal J, Umansky V. Elevated chronic inflammatory factors and myeloid-derived suppressor cells indicate poor prognosis in advanced melanoma patients. Int J Cancer 2015; 136(10):2352-60; PMID:25353097; https://doi.org/10.1002/ijc.29297
16. Huppa JB, Davis MM. T-cell-antigen recognition and the immunological synapse. Nat Rev Immunol 2003; 3(12):973-83; PMID:14647479; https://doi.org/10.1038/nri1245
17. Baniyash M. TCR zeta-chain downregulation:curtailing an excessive inflammatory immune response. Nat Rev Immunol 2004; 4(9):675-87;PMID:22858650; https://doi.org/10.1038/nri1434
18. Califano JA, Khan Z, Noonan KA, Rudraraju L, Zhang Z, Wang H, Goodman S, Gourin CG, Ha PK, Fakhry C, et al. Tadalafil augments tumor specific immunity in patients with head and neck squamous cell carcinoma. Clin Cancer Res 2015; 21(1):30-8; PMID:25564570; https://doi.org/10.1158/1078-0432.CCR-14-1716
19. Weed DT, Vella JL, Reis IM, De la Fuente AC, Gomez C, Sargi Z, Nazarian R, Califano J, Borrello I, Serafini P. Tadalafil reduces myeloid-derived suppressor cells and regulatory T cells and promotes tumor immunity in patients with head and neck squamous cell carcinoma. Clin Cancer Res 2015; 21(1):39-48; PMID:25320361; https://doi.org/10.1158/1078-0432.CCR-14-1711
20. Meyer C, Sevko A, Ramacher M, Bazhin AV, Falk CS, Osen W, Borrello I, Kato M, Schadendorf D, Baniyash M, et al. Chronic inflammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma model. Proc Natl Acad Sci U S A 2011; 108(41):17111-6; PMID:21969559; https://doi.org/10.1073/pnas.1108121108
21. Reichert TE, Day R, Wagner EM, Whiteside TL. Absent or low expression of the zeta chain in T cells at the tumor site correlates with poor survival in patients with oral carcinoma. Cancer Res 1998; 58(23):5344-7; PMID:9850063
22. Boniface JD, Poschke I, Mao Y, Kiessling R. Tumor-dependent down-regulation of the ζ-chain in T-cells is detectable in early breast cancer and correlates with immune cell function. Int J Cancer 2012; 131(1):129-39; PMID:21823123; https://doi.org/10.1002/ijc.26355
23. Enderle Y, Meid AD, Friedrich J, Grünig E, Wilkens H, Haefeli WE, Burhenne J. Dried blood spot technique for the monitoring of ambrisentan, bosentan, sildenafil, and tadalafil in patients with pulmonary arterial hypertension. Anal Chem 2015; 87(24):12112-20; PMID:26583764; https://doi.org/10.1021/acs.analchem.5b03077
24. Weide B, Martens A, Zelba H, Stutz C, Derhovanessian E, Di Giacomo AM, Maio M, Sucker A, Schilling B, Schadendorf D, et al. Myeloid-derived suppressor cells predict survival of patients with advanced melanoma:comparison with regulatory T cells and NY-ESO-1- or melan-A-specific T cells. Clin Cancer Res 2014; 20(6):1601-9; PMID:24323899; https://doi.org/10.1158/1078-0432.CCR-13-2508
25. Kelderman S, Heemskerk B, van Tinteren H, van den Brom RR, Hospers GA, van den Eertwegh AJ, Kapiteijn EW, de Groot JW, Soetekouw P, Jansen RL, et al. Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma. Cancer Immunol Immunother 2014; 63(5):449-58; PMID:24609989; https://doi.org/10.1007/s00262-014-1528-9
26. Dick J, Lang N, Slynko A, Kopp-Schneider A, Schulz C, Dimitrakopoulou-Strauss A, Enk AH, Hassel JC. Use of LDH and autoimmune side effects to predict response to ipilimumab treatment. Immunotherapy 2016; 8(9):1033-44; PMID:27485076; https://doi.org/10.2217/imt-2016-0083
27. Schilling B, Sucker A, Griewank K, Zhao F, Weide B, Görgens A, Giebel B, Schadendorf D, Paschen A. Vemurafenib reverses immunosuppression by myeloid derived suppressor cells. Int J Cancer 2013; 133(7):1653-63; PMID:23526263; https://doi.org/10.1002/ijc.28168
28. Jordan KR, Amaria RN, Ramirez O, Callihan EB, Gao D, Borakove M, Manthey E, Borges VF, McCarter MD. Myeloid-derived suppressor cells are associated with disease progression and decreased overall survival in advanced-stage melanoma patients. Cancer Immunol. Immunother 2013; 62(11):1711-22; PMID:24072401; https://doi.org/10.1007/s00262-013-1475-x
29. Pico de Coaña Y, Poschke I, Gentilcore G, Mao Y, Nyström M, Hansson J, Masucci GV, Kiessling R. Ipilimumab treatment results in an early decrease in the frequency of circulating granulocytic myeloid-derived suppressor cells as well as their Arginase1 production. Cancer Immunol Res 2013; 1(6):438; PMID:24777678; https://doi.org/10.1158/2326-6066.CIR-13-0184
30. Gebhardt C, Sevko A, Jiang H, Lichtenberger R, Reith M, Tarnanidis K, Holland-Letz T, Umansky L, Beckhove P, Sucker A, et al. Myeloid cells and related chronic inflammatory factors as novel predictive markers in melanoma treatment with ipilimumab. Clin Cancer Res 2015; 21(24):5453-9; PMID:26289067; https://doi.org/10.1158/1078-0432.CCR-15-0676
31. Umansky V, Sevko A. Melanoma-induced immunosuppression and its neutralization. Semin Cancer Biol 2012; 22:319-26; PMID:22349515; https://doi.org/10.1016/j.semcancer.2012.02.003
32. Kao J, Ko EC, Eisenstein S, Sikora AG, Fu S, Chen SH. Targeting immune suppressing myeloid-derived suppressor cells in oncology. Crit Rev Oncol Hematol 2011; 77(1):12-9; PMID:20304669; https://doi.org/10.1016/j.critrevonc.2010.02.004
33. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nature Rev Immunol 2009; 9(3):162-74; PMID:19197294; https://doi.org/10.1038/nri2506
34. Ren JP, Zhao J, Dai J, Griffin JW, Wang L, Wu XY, Morrison ZD, Li GY, El Gazzar M, Ning SB, et al. Hepatitis C virus-induced myeloid-derived suppressor cells regulate T-cell differentiation and function via the signal transducer and activator of transcription 3 pathway. Immunology 2016; 148(4):377-86; PMID:27149428; https://doi.org/10.1111/imm.12616
35. Ren JP, Wang L, Zhao J, Wang L, Ning SB, El Gazzar M, Moorman JP, Yao ZQ. Decline of miR-124 in myeloid cells promotes regulatory T-cell development in hepatitis C virus infection. Immunology 2017; 150(2):213-220; PMID:27753084; https://doi.org/10.1111/imm.12680
36. Wang L, Zhao J, Ren JP, Wu XY, Morrison ZD, El Gazzar M, Ning SB, Moorman JP, Yao ZQ. Expansion of myeloid-derived suppressor cells promotes differentiation of regulatory T cells in HIV-1+ individuals. AIDS 2016; 30(10):1521-31; PMID:26959508; https://doi.org/10.1097/QAD.0000000000001083
37. Kang X, Zhang X, Liu Z, Xu H, Wang T, He L, Zhao A. Granulocytic myeloid-derived suppressor cells maintain feto-maternal tolerance by inducing Foxp3 expression in CD4+CD25-T cells by activation of the TGF-β/β-catenin pathway. Mol Hum Reprod 2016; 22(7):499-511; PMID:27016139; https://doi.org/10.1093/molehr/gaw026
38. Li WQ, Qureshi AA, Robinson KC, Han J. Sildenafil use and increased risk of incident melanoma in US men:a prospective cohort study. JAMA Intern Med 2014; 174(6):964-70; PMID:24710960; https://doi.org/10.1001/jamainternmed.2014.594
39. Loeb S, Folkvaljon Y, Lambe M, Robinson D, Garmo H, Ingvar C, Stattin P. Use of phosphodiesterase type 5 inhibitors for erectile dysfunction and risk of malignant melanoma. JAMA 2015; 313(24):2449-55; PMID:26103029; https://doi.org/10.1001/jama.2015.6604
40. Dhayade S, Kaesler S, Sinnberg T, Dobrowinski H, Peters S, Naumann U, Liu H, Hunger RE, Thunemann M, Biedermann T, et al. Sildenafil Potentiates a cGMP-Dependent Pathway to Promote Melanoma Growth. Cell Rep 2016; 14(11):2599-610; PMID:26971999; https://doi.org/10.1016/j.celrep.2016.02.028
41. Arozarena I, Sanchez-Laorden B, Packer L, Hidalgo-Carcedo C, Hayward R, Viros A, Sahai E, Marais R. Oncogenic BRAF induces melanoma cell invasion by downregulating the cGMP-specific phosphodiesterase PDE5A. Cancer Cell 2011; 19(1):45-57; PMID:21215707; https://doi.org/10.1016/j.ccr.2010.10.029
42. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, Buzaid AC, Cochran AJ, Coit DG, Ding S, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009; 27(36):6199-206; PMID:19917835; https://doi.org/10.1200/JCO.2009.23.4799
43. Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbe C, Maio M, Binder M, Bohnsack O, Nichol G, et al. Guidelines for the evaluation of immune therapy activity in solid tumors:immune-related response criteria. Clin Cancer Res:Off J Am Assoc Cancer Res 2009; 15(23):7412-20; PMID:19934295; https://doi.org/10.1158/1078-0432.CCR-09-1624
44. Ware J, Jr, Kosinski M, Keller SD. A 12-item short-form health survey:construction of scales and preliminary tests of reliability and validity. Med Care 1996; 34(3):220-33; PMID:8628042; https://doi.org/10.1097/00005650-199603000-00003
45. Bullinger M, Kirchberger I, Ware J. Der deutsche SF-36 Health Survey Übersetzung und psychometrische Testung eines krankheitsübergreifenden Instruments zur Erfassung der gesundheitsbezogenen Lebensqualität. Z f Gesundheitswiss 1995; 3:21-36; https://doi.org/10.1007/BF02959944
46. Halama N, Michel S, Kloor M, Zoernig I, Benner A, Spille A, Pommerencke T, von Knebel DM, Folprecht G, Luber B, et al. Localization and density of immune cells in the invasive margin of human colorectal cancer liver metastases are prognostic for response to chemotherapy. Cancer Res 2011; 71(17):5670-7; PMID:21846824; https://doi.org/10.1158/0008-5472.CAN-11-0268
47. Halama N, Zoernig I, Berthel A, Kahlert C, Klupp F, Suarez-Carmona M, Suetterlin T, Brand K, Krauss J, Lasitschka F, et al. Tumoral immune cell exploitation in colorectal cancer metastases can be targeted effectively by anti-ccr5 therapy in cancer patients. Cancer Cell 2016; 29(4):587-601; PMID:27070705; https://doi.org/10.1016/j.ccell.2016.03.005
48. US FDA Center for Drug Evaluation and Research. Guidance for Industry. Bioanalytical Method Validation. 2001. http://www.fda.gov/downloads/Drugs/…/Guidances/ucm070107.pdf&usg=AFQjCNH9_-SV60XEIRd0uaX4tAN2plExQw&cad=rja
49. EMA. Guideline on Bioanalystical Method Validation. 2012. www.ema.europa.eu/docs/en_GB/document_library/Scientific_guidline/2011/08/WC500109686.pdf